Alturos Therapeutics, a biopharmaceutical company focused on developing transformative therapies for neurodegenerative diseases, has announced the advancement of its lead candidate ALTO135, into IND-enabling studies, aiming to accelerate clinical development timelines.
Alturos is developing small molecule therapies designed to target the earliest toxic triggers in Alzheimer’s disease, particularly protein oligomers that drive synaptic loss and neuronal death.
Alturos’ research is built on a pre-clinical drug discovery programme previously acquired from Galapagos (now Lakefront Biotherapeutics). ALT0135 is a derisked and potentially first-in-class, orally bioavailable small molecule with demonstrated central nervous system (CNS) penetration.
This programme aligns with Alturos’ strategy to advance innovative neuroprotective approaches with a new mechanism of action supported by robust in vitro and in vivo efficacy data. By addressing upstream disease drivers and modulating downstream pathways associated with neuronal toxicity, the platform offers a differentiated approach to treating neurodegenerative disorders.
